(Q43804970)

27 November 2017

title

Effects of tumour necrosis factor-alpha synthesis inhibitors on rat trinitrobenzene sulphonic acid-induced chronic colitis (English)

1 reference

27 November 2017

0 references

Bobin-Dubigeon C

1

1 reference

27 November 2017

Collin X

2

1 reference

27 November 2017

Grimaud N

3

1 reference

27 November 2017

Robert JM

4

1 reference

27 November 2017

Le Baut G

5

1 reference

27 November 2017

Petit JY

6

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

European Journal of Pharmacology

27 November 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

27 November 2017

volume

431

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

103-110

1 reference

Anti-inflammatory effects of a new tumour necrosis factor-alpha (TNF-alpha) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Treatment of Crohn's disease at the turn of the century

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Taming TNF: strategies to restrain this proinflammatory cytokine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Effects of octreotide treatment on early TNF-alpha production and localization in experimental chronic colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Inflammatory mediators of experimental colitis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Cytokines in inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Experimental immunomodulatory therapy of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

Treatment with 16,16'-dimethyl prostaglandin E2 before and after induction of colitis with trinitrobenzenesulfonic acid in rats decreases inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901410-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(01)01410-8

1 reference

27 November 2017

1 reference